The editorial staff did not participate in the production of this content
The Abrysvo vaccine helps prevent infections linked to respiratory syncytial virus in newborns. Firstly bronchiolitis, potentially serious in young children. The vaccine works by passive immunization, that is to say that it is pregnant women who are vaccinated, between 32 and 36 weeks of amenorrhea. The vaccination campaign began in France on 1is september.
A French study published Friday, November 14 in the journal Obstetrics and gynecology aimed to evaluate the safety of the Abrysvo vaccine for the mother and fetus. The risks studied? Premature birth, delivery within one week or three weeks following vaccination, stillbirth, low birth weight, cesarean section, peri or postpartum hemorrhage, preeclampsia/eclampsia/HELLP syndrome (hemorrhagic disease frequently associated with severe preeclampsia) and any serious cardiovascular event, including maternal death.
A point of vigilance for women vaccinated at 32 weeks of amenorrhea
In this work, EPI-PHARE, a scientific interest group between the National Medicines Safety Agency (ANSM) and the Cnam, relied on the national health database (SNDS), including all women who gave birth after 22 weeks of amenorrhea between September 15 and December 31, 2024.
In total, 29,032 women were vaccinated during the study period. To ensure that the group of unvaccinated women and the vaccinated group were comparable, the vaccinated women were matched with unvaccinated women with similar characteristics (history of prematurity, influenza vaccination during pregnancy, multiple pregnancy, etc.).
Results ? This observational study did not reveal any increased risk associated with vaccination with Abrysvo. A point of vigilance, however, for women vaccinated before or at 32 weeks of amenorrhea. “In these women, who represent only 6% of vaccinated women, a slight increase in the risk of premature birth cannot be excluded. If a causal link with vaccination cannot be established from this study, this trend, already reported in previous studies, is already the subject of reinforced monitoring.specifies the ANSM.
